DMAC logo

DIAMEDICA THERAPEUTICS INC

DMACNASDAQ
🏆 #3058 by market capEarnings Nov 10 · PostUS Equity
$8.20▼ $0.12 (−1.44%)
After hours · at close
🔔
Track DMAC
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.4%
7d▲ 5.4%
14d▲ 26.3%
30d▲ 28.3%
ytd▲ 2.9%
1y▲ 18.9%
🏦Market Cap
$442M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$8.17 – $8.24
52-Week Range
$5.25 – $10.42
Volume
$2.13B
Avg Volume
$2.24B
Shares Outstanding
53.9M
Next Earnings
Oct 21, 2026

Fundamentals Snapshot

Annual Revenue
$103M
Last Q Revenue
$24M
P/E Ratio
-11.6
P/S Ratio
0.0x
EPS (TTM)
$-0.70
Dividend Yield
0.00%
Dilution (1yr)
+9.7%

Why Investors Own DMAC

  • ✓High-growth profile — revenue up -8.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 28% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DMAC logo

DIAMEDICA THERAPEUTICS INC

DMAC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$34M▲ +28.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$29M▲ +31.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
47.0M▲ +9.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$15M▲ +$13M YoY
StockOtter · stockotter.space

About DIAMEDICA THERAPEUTICS INC

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$9.07
▲ +10.7% Upside
High Target$10.91
Low Target$7.24
Based on 10 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

DIAMEDICA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift DMAC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

DIAMEDICA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.